Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Trodelvy
Pharma
Failed Trodelvy first-line NSCLC trial shows better China data
Trodelvy-Keytruda showed a negative overall survival signal over Keytruda in the global phase 3 trial but a 35% positive trend in Chinese patients.
Angus Liu
Sep 12, 2026 9:45pm
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC
Jun 24, 2026 5:00pm
Gilead's Trodelvy stumbles in first-line NSCLC
Jun 9, 2026 11:14am
AZ, Daiichi's Datroway approved in first-line TNBC
May 22, 2026 11:32am
In endometrial cancer, Merck and Kelun score with sac-TMT
May 18, 2026 11:21am
Merck partner Kelun touts ph. 3 win for ADC in first-line NSCLC
Nov 24, 2025 10:56am
